Company: IOBT
Filing Date: 2025-04-25
Form Type: DEF 14A
Source: 0000950170-25-058699
Chunk: 41

Company: IO Biotech, Inc.
Filing Date: 2025-04-25
Form: DEF 14A
Chunk 41
---
 warrants held by Dr. Zocca exercisable within 60 days of April 11, 2025.

Consists of 84,632 shares of common stock and 271,592 shares of common stock issuable upon exercise of options held by Ms. Sullivan within 60 days of April 11, 2025.

Consists of 31,350 shares of common stock and 213,738 shares of common stock issuable upon exercise of options held by Dr. Ahmad within 60 days of April 11, 2025.

Consists of 249,490 shares of common stock issuable upon exercise of options and warrants held by Dr. Hirth exercisable within 60 days of April 11, 2025.

Consists of 207,770 shares of common stock issuable upon exercise of options and warrants held by Ms. Glaub exercisable within 60 days of April 11, 2025.

Consists of 139,079 shares of common stock issuable upon exercise of options held by Mr. Smith exercisable within 60 days of April 11, 2025.

Consists of 111,060 shares of common stock issuable upon exercise of options held by Dr. Elling exercisable within 60 days of April 11, 2025.

Consists of 83,114 shares of common stock issuable upon exercise of options held by Ms. Hunter exercisable within 60 days of April 11, 2025.

Consists of 77,761 shares of common stock issuable upon exercise of options held by Dr. Collins exercisable within 60 days of April 11, 2025.

Consists of all shares of common stock held by, or issuable upon exercise of securities held by, our directors and current executive officers that are exercisable within 60 days of April 11, 2025.

<div align='center'>31

ADDITIONAL INFORMATION</div>

Stockholder Proposals and Nominations

Pursuant to Rule 14a-8 under the Exchange Act, in order to be included in our proxy statement and form of proxy for the 2026 annual meeting of stockholders, stockholder proposals must be received at our principal executive offices, c/o Corporate Secretary, IO Biotech, Inc., Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark, no later than December 26, 2025, and must comply with additional requirements established by the SEC. Purs